IL282713A - Novel anti-TNFR2 antibody agonistic molecules - Google Patents

Novel anti-TNFR2 antibody agonistic molecules

Info

Publication number
IL282713A
IL282713A IL282713A IL28271321A IL282713A IL 282713 A IL282713 A IL 282713A IL 282713 A IL282713 A IL 282713A IL 28271321 A IL28271321 A IL 28271321A IL 282713 A IL282713 A IL 282713A
Authority
IL
Israel
Prior art keywords
antibody molecules
agonistic anti
tnfr2 antibody
novel agonistic
anti tnfr2
Prior art date
Application number
IL282713A
Other languages
English (en)
Hebrew (he)
Original Assignee
Bioinvent Int Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioinvent Int Ab filed Critical Bioinvent Int Ab
Publication of IL282713A publication Critical patent/IL282713A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL282713A 2018-11-01 2021-04-27 Novel anti-TNFR2 antibody agonistic molecules IL282713A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18203996 2018-11-01
PCT/EP2019/080003 WO2020089473A2 (en) 2018-11-01 2019-11-01 Novel agonistic antibody molecules

Publications (1)

Publication Number Publication Date
IL282713A true IL282713A (en) 2021-06-30

Family

ID=64109795

Family Applications (1)

Application Number Title Priority Date Filing Date
IL282713A IL282713A (en) 2018-11-01 2021-04-27 Novel anti-TNFR2 antibody agonistic molecules

Country Status (11)

Country Link
US (2) US12139547B2 (https=)
EP (1) EP3873935A2 (https=)
JP (1) JP7664833B2 (https=)
KR (1) KR20210087466A (https=)
CN (3) CN121248780A (https=)
AU (1) AU2019370999A1 (https=)
BR (1) BR112021008007A2 (https=)
CA (1) CA3117756A1 (https=)
IL (1) IL282713A (https=)
MX (2) MX2021005151A (https=)
WO (1) WO2020089473A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220193196A1 (en) * 2019-05-28 2022-06-23 The Walter And Eliza Hall Institute Of Medical Research Methods for Modulating T Cell Activation
TWI878554B (zh) 2020-06-12 2025-04-01 大陸商南京維立志博生物科技股份有限公司 結合ｔｎｆｒ２的抗體及其用途
KR20230034367A (ko) * 2020-07-02 2023-03-09 바이오로직 디자인 리미티드 항-종양 괴사 인자 수용체 (tnfr2) 항체 및 그 용도
EP4067381A1 (en) * 2021-04-01 2022-10-05 Julius-Maximilians-Universität Würzburg Novel tnfr2 binding molecules
CN117836325A (zh) * 2021-06-22 2024-04-05 盛禾(中国)生物制药有限公司 一种抗tnfr2抗体及其制备方法和应用
CN115925929A (zh) 2021-09-22 2023-04-07 上海康岱生物医药技术股份有限公司 抗tnfr2单克隆抗体及其应用
WO2023154799A1 (en) 2022-02-14 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy for treating cancer
CA3256751A1 (en) * 2022-05-26 2023-11-30 Pfizer Inc. Anti-TNFR2 antibodies and their methods of use
JP2026503077A (ja) * 2023-01-09 2026-01-27 オデッセイ セラピューティクス，インコーポレイテッド 抗ｔｎｆｒ２抗原結合タンパク質及びその使用
CN121013905A (zh) * 2023-03-31 2025-11-25 艾菲赛尔治疗株式会社 已经引入至编码特异性结合于TNFR2的Stefin A蛋白变体或包括该蛋白变体的融合蛋白的核酸中的基因修饰的细胞，及其用途
WO2025250701A1 (en) * 2024-05-28 2025-12-04 Nektar Therapeutics Anti-tumor necrosis factor receptor 2 (tnfr2) antibodies and methods of use
WO2026022721A1 (en) * 2024-07-26 2026-01-29 Janssen Biotech, Inc. Anti-tnfr2 antibodies
CN119591710B (zh) * 2024-11-12 2026-01-13 澳门大学 一种激动性tnfr2单域抗体及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
EP3936137A1 (en) 2013-02-07 2022-01-12 The General Hospital Corporation Methods for expansion or depletion of t-regulatory cells
CN115043943A (zh) * 2015-05-15 2022-09-13 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
US20190135929A1 (en) 2015-08-28 2019-05-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
CA3004830A1 (en) * 2015-11-11 2017-05-18 Opi Vi- Ip Holdco Llc Composition and methods for anti-tnfr2 antibodies
US11859002B2 (en) * 2016-05-13 2024-01-02 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor 2 antibodies

Also Published As

Publication number Publication date
JP7664833B2 (ja) 2025-04-18
JP2022514179A (ja) 2022-02-10
US20250066492A1 (en) 2025-02-27
MX2021005151A (es) 2021-07-15
US12139547B2 (en) 2024-11-12
US20220002426A1 (en) 2022-01-06
MX2025014435A (es) 2026-01-07
BR112021008007A2 (pt) 2021-08-10
KR20210087466A (ko) 2021-07-12
CA3117756A1 (en) 2020-05-07
CN121248781A (zh) 2026-01-02
WO2020089473A2 (en) 2020-05-07
WO2020089473A9 (en) 2020-10-01
CN112996812A (zh) 2021-06-18
CN121248780A (zh) 2026-01-02
CN112996812B (zh) 2025-09-12
WO2020089473A3 (en) 2020-07-16
AU2019370999A1 (en) 2021-05-20
EP3873935A2 (en) 2021-09-08

Similar Documents

Publication Publication Date Title
IL282713A (en) Novel anti-TNFR2 antibody agonistic molecules
IL283812A (en) Humanized antibody against human pd–1
SG11202102882YA (en) Antigen-binding molecule comprising altered antibody variable region
SG11202106214YA (en) Novel anti-ccr8 antibody
GB201811403D0 (en) Antibody molecules
IL259492B (en) Humanized anti-cll-1 antibodies
EP3307322A4 (en) Humanized anti-cd40 antibodies and uses thereof
ZA202004908B (en) Bispecific antibody
EP3181587A4 (en) Anti-human il-17 monoclonal antibody and use thereof
IL282756A (en) Humanized antibodies against SIRPα
IL263936A (en) Humanized monoclonal antibodies targeting hptp-beta)ve-ptp)
GB201709970D0 (en) Bispecific antigen-binding molecules
EP3137502A4 (en) Humanized antibodies against ceacam1
IL271832A (en) Bispecific antibodies against PD1 and against TIM3
ZA202205226B (en) Ri-labeled humanized antibody
IL282715A (en) Novel antagonistic anti tnfr2 antibody molecules
EP3590964A4 (en) IMPROVED MONOCLONAL ANTI-VEGFR-2 ANTIBODY
DK3684813T3 (da) Agonistiske cd40-antistoffer
SMT202200360T1 (it) Anticorpi umanizzati anti clever-1 e loro utilizzo
EP3325511A4 (en) HUMANIZED MONOCLONAL SPECIFIC ANTIBODIES AGAINST SYNDECAN-1
EP3677677A4 (en) MONOCLONAL ANTIBODY AGAINST HSV GB OR CORRESPONDING ANTIGEN BINDING FRAGMENT
IL289247A (en) Bispecific molecules block an immune checkpoint
GB201911211D0 (en) Monoclonal antibodies against ambra-1
EP3891180C0 (en) HUMANIZED ANTIBODIES AGAINST IL17BR
EP3710048A4 (en) HUMANIZED MONOCLONAL 2C7 ANTIBODY DIRECTED AGAINST LIPOOLIGOSACCHARIDE (LOS) EPITOPE ANEISSERIA GONORRHOEAE